TEMET-HD
Randomised, double-blind, placebo-controlled study to evaluate the effect of metformin, an AMPK activator, on cognitive measures of progression in Huntington's disease patients.
Phase 3 study testing an investigational treatment in Huntington's disease.
Temporarily haltedPhase IIINot specifiedCTIS (EU)Treatment trial
- EU sites are temporarily halted (CTIS (EU))
Recruiting in: Spain
Sponsor: IIS La Fe
Preparing a short plain-English summary.